Park Medi World Limited (NSE: PARKHOSPS) has been recognised with three honours at the prestigious Healthcare Pioneers of Delhi 2026 awards. The accolades were presented by Smt. Rekha Gupta, Hon’ble Chief Minister of Delhi, at The Imperial Hotel, Janpath, New Delhi on 20th September 2026. The recognition highlights the Group’s commitment to clinical outcomes, advanced medical technology, and expanding presence across North India.

Lifetime Achievement Award

Dr. Ajit Gupta, Founder & Chairman, received the Lifetime Achievement Award. This honour reflects his long-standing dedication to healthcare excellence.

Future Healthcare Leader of the Year

Dr. Ankit Gupta, Managing Director, was named Future Healthcare Leader of the Year. This recognition underscores his leadership in scaling capacity and investing in advanced medical technology.

Excellence in Advanced Medical Technology & Patient Care

Park Group of Hospitals was awarded Excellence in Advanced Medical Technology & Patient Care. This accolade highlights the Group’s commitment to providing high-quality, affordable healthcare services.

As Park Medi World Limited continues to expand its network, it aims to build a dependable, technology-enabled healthcare ecosystem that serves both metropolitan and regional communities across North India. For more information, visit www.parkhospital.in.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Park Medi World Limited

Park Medi World Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Park holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG stands at 7.91 — severely stretched. Any earnings miss could trigger a sharp de-rating. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock gains 2.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. The stock rises -0.7% in three months on 9.6% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Park Medi World Limited.

Biocon Limited (NSE: BIOCON) announced that its Pertuzumab biosimilar has become the first biosimilar to secure a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This approval recommendation under the new tailored clinical approach marks a significant milestone for Biocon Biologics Limited, a wholly-owned subsidiary of Biocon Limited. The biosimilar, marketed under the brand name Pebrilzo®, is indicated for the treatment of HER2-positive breast cancer across multiple disease stages.

Extensive Clinical and Analytical Validation

The positive CHMP opinion follows a comprehensive review of the marketing authorization application submitted by Biocon Biologics Ireland Limited. Extensive orthogonal, state-of-the-art structural and functional analytical characterization, together with comparative clinical pharmacokinetic data, demonstrated that Pebrilzo® is highly similar to the reference biologic, with no clinically meaningful differences in quality, safety, or efficacy.

Expanding Access to Biologic Therapies

Shreehas Tambe, CEO & Managing Director of Biocon, said: “The positive CHMP opinion for our Pertuzumab biosimilar marks an important step toward expanding access to biologic therapies for patients with HER2-positive breast cancer in Europe.” This approval reflects an important milestone in the evolution of biosimilar science and greater regulatory confidence on advanced analytical and clinical pharmacology evidence to establish biosimilarity.

As the first monoclonal antibody biosimilar to receive a positive CHMP opinion under EMA’s tailored clinical development approach, this approval is a testament to Biocon’s commitment to providing affordable, life-changing medicines to patients worldwide.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon moves sideways over three months, with neither buyers nor sellers taking control. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock holds at 44% of its 52-week range with RSI at 35. In other words, neither side has a clear edge right now. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Laurus Labs Limited (NSE: LAURUSLABS) has announced its financial results for FY26, showcasing a robust performance with a 23% increase in revenue to ₹6,813 crore. The company’s EBITDA margin stood at 26.8%, reflecting its strong operational efficiency and strategic growth initiatives. The company’s total capital expenditure for FY26 was ₹1,826 crore, marking a 64% year-over-year increase. Looking ahead, Laurus Labs is guiding for an EBITDA margin of over 30% starting FY27, driven by accelerated capital expenditures and strategic investments in its manufacturing and technology platforms.

Operational Highlights

Laurus Labs has demonstrated a consistent track record in multi-site manufacturing capabilities, with a focus on quality, regulatory compliance, and innovation. The company’s manufacturing network spans 15 sites globally, including new and expanding facilities in Visakhapatnam and Hyderabad. The company has invested over ₹4,300 crore in building a diversified portfolio across various technologies, including API, formulations, peptides, fermentation, gene therapy, and antibody drug conjugates.

Future Growth Prospects

With a healthy order book and a strong internal pipeline, Laurus Labs is well-positioned to meet growing customer demands. The company plans to continue its accelerated capital expenditure, targeting over ₹3,000 crore in FY27 and FY28 to further strengthen its manufacturing network and technological capabilities. As a result, the company expects to achieve a higher asset turnover ratio, aligning with its long-term growth strategy.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Laurus Labs Limited

Laurus Labs Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Laurus gains 38.3% over three months and trades near its 52-week highs. The PEG stands at 24.10 — severely stretched. Any earnings miss could trigger a sharp de-rating. No meaningful dividend — total return is entirely dependent on capital appreciation. Sellers drive 2.2x the volume of buyers. Furthermore, they controlled 11 of recent sessions versus 19 for buyers — a clear distribution signal. Revenue grows at 3.8% CAGR and the PEG stands at 24.10. The growth does not match the price the market asks. Furthermore, flat price action adds no technical catalyst. A lower price or faster revenue growth would improve the odds. Check Fundamentals of Laurus Labs Limited.